Shares of West Pharmaceutical Services surged 6.5% to $430 after the injectable-drug packaging maker posted third-quarter results that crushed Wall Street expectations across every major metric, then raised its full-year outlook for the third consecutive quarter. The beat forces investors to weigh whether the GLP-1 boom justifies a stock now trading at roughly 45 times its new full-year adjusted EPS guidance.
• Revenue and Earnings Blew Past Forecasts by a Wide Margin
West reported adjusted earnings of $2.66 per share on revenue of $874.5 million, beating Wall Street forecasts of $2.20 per share and $827.1 million in sales. That's a 21% EPS beat — the fifth straight quarter the company has topped estimates.
Adjusted EPS came in $0.47 above the midpoint of the company's own guidance from just three months ago , signaling management itself underestimated demand.
• The GLP-1 Wave Is Reshaping the Product Mix
GLP-1-related revenues reached about 12% of sales in Q3, while high-value product components delivered roughly 20% organic growth — the kind of specialty packaging used for biologics and weight-loss injectables. These high-value lines now account for 53% of total sales, and the mix keeps shifting toward the highest-margin, fastest-growing segments.
Adjusted operating margin expanded 420 basis points (about four percentage points) to 25.3% , meaning West keeps more of every dollar it earns.
• Raised Guidance Signals Confidence Through Year-End
Full-year sales guidance rose to $3.41–$3.42 billion (from $3.345–$3.38 billion) and adjusted EPS to $9.38–$9.48 (from $8.85–$9.05). That bottom-line lift of roughly 5% at the midpoint reflects both volume gains and richer pricing on premium components. West also repurchased $231 million of stock in the quarter, bringing year-to-date buybacks to $685 million , while boosting its quarterly dividend 18% to $0.26 per share.
• Valuation Now Tests Investor Patience At $430, WST trades at about 45x the midpoint of its new $9.43 adjusted-EPS guide — a steep price even for a company riding powerful pharmaceutical trends. TD Cowen raised its price target to $500 , and Barclays lifted its own target to $500 with an Overweight rating. Yet the stock already sits above many older targets. If GLP-1 adoption plateaus or biologics orders normalize, the premium unwinds fast. For now, execution is flawless — the question is what's already priced in.